Form 4: Sarepta COO Sells Shares for Tax Obligations
Insider Transaction Report
Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, sold 13,187 shares of common stock to cover tax liabilities from restricted stock unit vesting.
Summary
- Ian Michael Estepan, Chief Operating Officer of Sarepta Therapeutics, Inc. (SRPT), reported a sale of common stock.
- The transaction involved the disposition of 13,187 shares on December 16, 2025.
- The shares were sold at a weighted average price of $22.31 per share, with prices ranging from $22.29 to $22.35.
- The sale was conducted to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.
- This transaction was made pursuant to a Rule 10b5-1(c) plan.
- Following this transaction, Estepan directly beneficially owns 193,300 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral. The transaction is a routine sale to cover tax obligations from restricted stock unit vesting, explicitly noted as being made pursuant to a Rule 10b5-1 plan, which is a common practice for executives and does not indicate a change in sentiment towards the company's prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: A minor reduction in the Chief Operating Officer's direct beneficial ownership, though the transaction is routine and tax-related, made under a pre-planned Rule 10b5-1 arrangement.
Key Dates
| Date | Description |
|---|---|
| 12/16/2025 | Date of transaction for the sale of common stock by Ian Michael Estepan. |
| 12/18/2025 | Signature date of the reporting person's attorney-in-fact for the Form 4 filing. |
Recommendation
holdThe sale of shares by the Chief Operating Officer is explicitly stated as being for tax obligations related to restricted stock unit vesting and was made pursuant to a Rule 10b5-1 plan. This is a common and routine practice for executives to manage their compensation and does not inherently signal a change in the company's fundamentals or the executive's confidence. Therefore, it does not warrant a change from a 'hold' recommendation based solely on this filing.
Keywords
Sarepta Therapeutics, SRPT, Form 4, Insider Trading, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Obligations, Ian Michael Estepan, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.